Attendee search 

Petrone Group Asia Pacific Pte Ltd gives support to Sponsors , CROs , Clinical Research Institutes , Pharma and Biotech company for IMP management and Comparators sourcing.

We are a specialized company in high quality furniture of Investigational Medicinal Product (IMP) and in services for international clinics experimentations , our service has high flexibility in managing clinical trials from phase I to phase IV according to customers’ specific requirements.

Alternative protein with microalgae

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Acne, Rosacea, and Actinic keratosis. LEO Pharma is continously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets.

LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.

To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.

We are keen for Licensing-in Assets for Global and Regional Rights for following:
(1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases
(2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities.
(3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets
(4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology

iX Biopharma is established in 2008, and listed on Singapore Stock Exchange (Catalist Board) in 2015. iX is a specialist in novel wafer formulations using patented sublingual delivery technology, WaferiXTM , which is patented in China to 2033. R&D and manufacturing at wholly-owned GMP licensed facility in Melbourne, Australia.

TPG旗下医疗健康投资公司 关注肿瘤设备及创新药